07 Aug 2025
12m
Astria Therapeutics licensed its HAE treatment, Navenibart, to Kaken Pharmaceutical for the Japanese market. It is a kallikrein inhibitor that is in phase 3, and is dosed up to every six months
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.